Lower respiratory tract inflammation in chronic bronchitis: Evaluation by bronchoalveolar lavage and changes associated with treatment with immucytal, a biological response modifier

B. Balbi, A. Aufiero, A. Pesci, S. Oddera, P. Zanon, G. A. Rossi, D. Olivieri

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic bronchitis (CB) is characterized by inflammatory changes in the bronchial tissue and by recurrent bronchitis exacerbations. In addition, defective systemic and local immune mechanisms have been demonstrated and biologic response modifiers (BRMs) have been recently introduced for clinical use in patients with CB. We studied 24 patients with CB by bronchoalveolar lavage (BAL), before and after a 4-week treatment protocol with inhaled Immucytal (Pierre-Fabre Pharma Srl, Milan, Italy), a BRM composed of bacterial ribosomal fractions and membrane proteoglycanes. Compared with normal controls (NC), before treatment BAL in patients with CB contained increased proportions of neutrophils (NC, 0.8±0.2 percent; CB, 3±1 percent), of eosinophils (NC, 0.1±0.02 percent; CB, 0.6±0.2 percent); and of lymphocytes (NC, 6±1 percent; CB, 13±2 percent; p+ and CD8+ lymphocytes (p3 neutrophils per milliliter of BAL before, 1.5±0.5x103 neutrophils per milliliter after; p

Original languageEnglish
Pages (from-to)819-826
Number of pages8
JournalChest
Volume106
Issue number3
Publication statusPublished - 1994

Keywords

  • bacterial extracts
  • biological response modifiers
  • bronchoalveolar lavage
  • chronic bronchitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Lower respiratory tract inflammation in chronic bronchitis: Evaluation by bronchoalveolar lavage and changes associated with treatment with immucytal, a biological response modifier'. Together they form a unique fingerprint.

Cite this